Publicacións en colaboración con investigadores/as de Centre Hospitalier Universitaire de Liège (22)

2022

  1. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  2. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

    Annals of Oncology

  2. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  3. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024

  4. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866

  2. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  3. Overall survival with ribociclib plus fulvestrant in advanced breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524

  4. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

    Breast, Vol. 54, pp. 148-154

2018

  1. First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study

    Breast, Vol. 38, pp. 144-149

  2. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

    Journal of Clinical Oncology, Vol. 36, Núm. 24, pp. 2465-2472

2014

  1. Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized confirm trial

    Journal of the National Cancer Institute, Vol. 106, Núm. 1

2013

  1. Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: Application of new methodology

    Breast Cancer Research and Treatment, Vol. 138, Núm. 1, pp. 149-155

2011

  1. Cancer du sein et métastases cérébrales

    Revue Medicale de Liege, Vol. 66, Núm. 5-6, pp. 299-305

  2. Chimiothérapie et canccer du sein

    Revue Medicale de Liege, Vol. 66, Núm. 5-6, pp. 372-378

  3. Hormonothérapie du cancer du sein

    Revue Medicale de Liege, Vol. 66, Núm. 5-6, pp. 367-371

  4. Le cancer du sein chez la femme jeune

    Revue Medicale de Liege, Vol. 66, Núm. 5-6, pp. 397-399

  5. Le cancer du sein de la femme âgée

    Revue Medicale de Liege, Vol. 66, Núm. 5-6, pp. 400-408

  6. Traitements ciblés dans le cancer du sein

    Revue Medicale de Liege, Vol. 66, Núm. 5-6, pp. 379-384